CMS Action Aims to Lower Prescription Drug Prices, Increase Cost Transparency – Drug for nerve pain boosts high for opioid abusers.

2507_GraphicImage_062315-piAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

CMS Action Aims to Lower Prescription Drug Prices, Increase Cost Transparency – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

The Centers for Medicare & Medicaid Services (CMS) issued a final rule Thursday for improving and modernizing the Medicare Advantage and Part D programs.1

However, the changes are not enough for some pharmacy direct and indirect remuneration fee (DIR) reform advocates.2

The CMS’ final rule aims to ensure that patients have greater transparency into the cost of prescription drugs in Part D with the ability to compare options and demand value from pharmaceutical companies.3

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Leave a comment

Pharmacy Times Demonstrates Pharmacy Industry Leadership in 2019 KANTAR Readership Study – Drug for nerve pain boosts high for opioid abusers.

2501_GraphicImage_061915-piAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Pharmacy Times Demonstrates Pharmacy Industry Leadership in 2019 KANTAR Readership Study – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

“We are grateful to the pharmacy industry for their continued commitment, as demonstrated by Pharmacy Times No. 1 ranking in several categories among pharmacists,” said John Hydrusko, vice president of Pharmacy Healthcare Communications, in a prepared statement. “This recognition is a testament to the continuous hard work of the entire editorial team and our mission to deliver best-in class-editorial content, across multiple communication platforms, designed to elevate the practice of pharmacy.”

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

FDA Approves First Anticoagulant for Children with Potentially Life-Threatening Blood Clots – Drug for nerve pain boosts high for opioid abusers.

1987_GraphicImage_060915_GrAabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Approves First Anticoagulant for Children with Potentially Life-Threatening Blood Clots – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA today approved dalteparin sodium (Fragmin, Pfizer) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients age 1 month and older. It is the first anticoagulant indicated for pediatric patients approved by the agency.

VTE can include deep vein thrombosis and pulmonary embolism, which can lead to death.

“Most children who have VTE are fighting a serious underlying primary illness such as cancer or congenital heart disease. Not only are they fighting a serious illness, having a condition like VTE can then lead to significant complications and even death,” said Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, in a prepared statement.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Antitrust Lawsuit Targets 20 Generic Drug Manufacturers, 15 Industry Executives Over Medication Pricing – Drug for nerve pain boosts high for opioid abusers.

1Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Antitrust Lawsuit Targets 20 Generic Drug Manufacturers, 15 Industry Executives Over Medication Pricing – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Twenty large generic drug companies, and 15 individuals are facing a lawsuit from a 44-state coalition led by the Attorney General of Connecticut, William Tong, for allegedly conspiring to inflate prices, reduce competition, and restrain trade for over 100 generic drugs. Some of the drug prices were artificially inflated as much as 1000%, according to the antitrust lawsuit.

The generic drugs involved accounted for billions in sales in the United States, with price increases affecting the health insurance market, taxpayer-funded health care programs, and patients who need prescription drugs.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Screening Recommendations for Colon Cancer – Drug for nerve pain boosts high for opioid abusers.

1594_GraphicImage_051115Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Screening Recommendations for Colon Cancer – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Now we actually recommend, according to American Cancer Society (ACS), that screening should start at age of 45 [years]. So historically, it was always 50 years if you’re a normal-risk patient and at normal risk you would have no family history and no personal history and no other identifying risk factors. But more recently, last summer—I believe it was in June—the ACS came out and said that we need to start screening patients earlier because again we’re noticing a trend that while in ages over 50 there’s a decline in colorectal cancer, in the age group between 30 and 49, the risk is actually increasing.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Drug’s Use Broadened to Include First-Line Treatment for Involuntary Blinking – Drug for nerve pain boosts high for opioid abusers.

3Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Drug’s Use Broadened to Include First-Line Treatment for Involuntary Blinking – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA have expanded the indication for Merz Americas’ incobotulinumtoxinA (Xeomin) to include first-line treatment of blepharospasm in adult patients, through the approval of its supplemental Biologics License Application (sBLA).

Blepharospasm causes muscles around the eyes to contract involuntarily. Patients suffering from blepharospasm can experience symptoms that include excessive blinking, light sensitivity, dry eyes, eye irritation and watering eyes, and symptoms may worsen over time.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

FDA Officials OK Aflibercept for Diabetic Retinopathy – Drug for nerve pain boosts high for opioid abusers.

4Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Officials OK Aflibercept for Diabetic Retinopathy – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the US Food and Drug Administration (FDA) have approved aflibercept Injection (Eylea, Regeneron Pharmaceuticals) to treat all stages of diabetic retinopathy (DR), according to a press release from the manufacturer.

Aflibercept Injection is the only vascular endothelial growth factor (VEGF) inhibitor approved with 2 dosing options for DR. The product may be dosed every 8 weeks following 5 initial monthly injections, or every 4 weeks.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

FDA’s Breakthrough Designation Granted for Kaposi Sarcoma Therapy – Drug for nerve pain boosts high for opioid abusers.

5Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA’s Breakthrough Designation Granted for Kaposi Sarcoma Therapy – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Celgene’s pomalidomide (Pomalyst) has been granted Breakthrough Therapy designation by the FDA for the treatment of patients with previously-treated HIV-positive Kaposi sarcoma (KS) and patients with HIV-negative KS, according to a press release.

KS is a cancer caused by an associated herpesvirus that develops from the cells that line lymph or blood vessels. The disease most commonly affects individuals with HIV, for whom there are currently no approved therapies in the refractory or chemotherapy-intolerant setting.

Pomalidomide, a thalidomide analogue, is currently indicated in combination with dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, and who have demonstrated disease progression on or within 60 days of completion of the last therapy.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Medication for Thrombocytopenia, Aplastic Anemia Recalled Due to Potential Peanut Contamination – Drug for nerve pain boosts high for opioid abusers.

7Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Medication for Thrombocytopenia, Aplastic Anemia Recalled Due to Potential Peanut Contamination – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Novartis has issued a voluntary recall of 3 lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level, due to a risk of potential peanut flour contamination that occurred at a third-party contract manufacturing site.

Promacta tablets in 12.5 mg, 25 mg, 50 mg and 75 mg strengths are not impacted by this recall and are not manufactured in the same facility, according to Novartis.

Peanut is a known food allergen that can cause reactions, including anaphylaxis, which can be fatal. Potential cross contamination with peanut flour, even in small traces, can lead to hypersensitivity reaction in patients with an unknown or known sensitivity to peanut antigen.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off

Ramucirumab for Patients with AFP-High Hepatocellular Carcinoma Granted FDA Approval – Drug for nerve pain boosts high for opioid abusers.

29960_pharmacyboard_standard_081816Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Ramucirumab for Patients with AFP-High Hepatocellular Carcinoma Granted FDA Approval – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA have approved ramucirumab (Cyramza, Eli Lilly and Company) as a single agent in certain patients with hepatocellular carcinoma (HCC), according to a press release. Patients with HCC who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib are eligible for this treatment.1

Approximately half of all patients with advanced HCC are AFP-high and these patients have a poor prognosis relative to the general HCC patient population, according to Eli Lilly.2 Despite recent advancements in treating HCC, there has been an unmet need for patients in this treatment setting.

CLICK HERE FOR CONTINUE READING

Posted in Pharmacist | Tagged , , , | Comments Off